Addition of neoadjuvant chemotherapy to a ‘quadrifecta’ composite in radical cystectomy
BJU International · 2024
DOI: 10.1111/bju.16331 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, 2024. Verfasst von David D'Andrea und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Cystectomy, Urinary Bladder Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To evaluate the impact of incorporating neoadjuvant chemotherapy (NAC) into the ‘quadrifecta’ outcomes composite for reporting outcomes of radical cystectomy (RC) creating a pentafecta score. Patients and Methods This is a retrospective multicentre analysis of patients treated with RC, with or without NAC, for bladder cancer between 2002 and 2023. The primary outcome was the effect of adding NAC to a quadrifecta outcomes composite on cancer‐specific (CSS) and overall survival (OS). The quadrifecta outcomes composite included a yield of ≥16 lymph nodes, negative soft tissue surgical margin, absence of major complication within 30 days from surgery, and no delay in RC.
Results
A total of 590 patients were included in the analyses. A total of 233 (39.5%) patients achieved all quadrifecta outcomes and 82 (13.9%) patients were additionally treated with NAC, achieving the pentafecta. Achieving the quadrifecta outcomes composite was significantly associated with better CSS (hazard ratio [HR] 0.49, 95% confidence interval [CI] 0.32–0.75; P = 0.001) and OS (HR 0.48, 95% CI 0.34–0.69; P < 0.01). The addition of NAC to the quadrifecta composite outcomes significantly improved the discrimination of patients more likely to have better CSS (HR 0.21, 95% CI 0.08–0.57; P = 0.002) and OS (HR 0.26, 95% CI 0.12–0.55; P < 0.01).
Conclusion
We propose a new pentafecta that may serve as a tool for standardising outcomes reporting and measuring the quality of RC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Medical University of Vienna, Vienna, Austria.
- Department of Urology, AOU Città della Salute e della Scienza, Torino School of Medicine, Turin, Italy.
- Department of Urology, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
- Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- UOC Urologia, Azienda Ospedaliera Universitaria Integrata Di Verona, Verona, Italy.
ORCID-Profile: David D'Andrea, Francesco Soria, Marco Moschini, Ekaterina Laukhtina, Alessandro Antonelli, Jeremy Yuen-Chun Teoh
Zitieren
APA
D'Andrea, D., Soria, F., Moschini, M., Laukhtina, E., Hurle, R., Mancon, S., Antonelli, A., Teoh, J. Y., Shariat, S. F., & Pradere, B. (2024). Addition of neoadjuvant chemotherapy to a ‘quadrifecta’ composite in radical cystectomy. BJU International. https://doi.org/10.1111/bju.16331
Vancouver
D'Andrea D, Soria F, Moschini M, Laukhtina E, Hurle R, Mancon S, et al. Addition of neoadjuvant chemotherapy to a ‘quadrifecta’ composite in radical cystectomy. BJU International. 2024. doi:10.1111/bju.16331
BibTeX
@article{DAndrea2024,
author = {D'Andrea, David and Soria, Francesco and Moschini, Marco and Laukhtina, Ekaterina and Hurle, Rodolfo and Mancon, Stefano and Antonelli, Alessandro and Teoh, Jeremy Yuen-Chun and Shariat, Shahrokh F and Pradere, Benjamin},
title = {Addition of neoadjuvant chemotherapy to a ‘quadrifecta’ composite in radical cystectomy},
journal = {BJU International},
year = {2024},
doi = {10.1111/bju.16331}
}
EUVIMED